PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des Personnes). This Phase I clinical trial will recruit its first subjects before end 2009. Patented until 2030, Fentanyl Lauriad® is based on the same muco-adhesive technology already validated with Loramyc®, BioAlliance already marketed drug. This sustained release new product is dedicated to the treatment of cancer chronic pain.
